RxDoctor Payments DataLook up a doctor →

Dee Guy

Family · Tuscaloosa, ALNPI 1396150116

Payments from drug & device makers

$13,510in general payments, 2019–2025

Across 725 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AstraZeneca$970
  • Pfizer$682
  • Daiichi Sankyo Inc.$681
  • E.r. Squibb & Sons, L.L.C.$652
  • Incyte Corporation$609
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$5554%
  • Food & beverage$12,67194%
  • Education$2842%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis114$2,383
AstraZeneca(2 entities)46$970
Pfizer48$682
Daiichi Sankyo Inc.39$681
E.r. Squibb & Sons, L.L.C.48$652
Incyte Corporation31$609
Seagen Inc.27$543
Merck27$465
Amgen27$432
GSK23$418
Gilead(2 entities)22$376
Johnson & Johnson21$361
Sanofi11$290
Takeda Pharmaceuticals U.S.A., Inc.11$266
Bristol Myers Squibb12$252
Eisai Inc.14$244
Lilly USA, LLC14$239
Array Biopharma Inc14$225
Blueprint Medicines Corporation8$207
Stemline Therapeutics Inc.9$206
AbbVie10$199
Genentech USA, Inc.9$185
Bayer9$170
Beone Medicines USA, Inc.11$167
Pharmaessentia USA Corporation7$153
Regeneron Healthcare Solutions, Inc.8$142
Deciphera Pharmaceuticals Inc.7$138
Karyopharm Therapeutics Inc.7$130
Myriad Genetic Laboratories, Inc.5$115
Boehringer Ingelheim4$111
Beigene USA, Inc.7$109
Pharmacyclics LLC, An Abbvie Company7$106
Jazz Pharmaceuticals Inc.4$92
Astellas Pharma US Inc5$90
Progenics Pharmaceuticals, Inc.4$71
Agios Pharmaceuticals, Inc.4$70
Sumitomo Pharma America, Inc.4$68
ADC Therapeutics America, Inc.4$68
EMD Serono, Inc.3$53
Acrotech Biopharma Inc.3$47
Taiho Oncology, Inc.3$47
Myovant Sciences Inc.3$45
Sobi, Inc2$44
Pharmacosmos Therapeutics Inc.2$43
Genmab U.S., Inc.2$39
Mirati Therapeutics, Inc.2$38
Exelixis Inc.1$36
Servier Pharmaceuticals LLC2$36
Rigel Pharmaceuticals, Inc.2$36
Morphosys, US Inc.2$35
Immunocore Limited1$30
AVEO Pharmaceuticals, Inc.1$29
Tersera Therapeutics LLC1$27
EUSA Pharma (US) LLC1$23
Novocure Inc.1$23
Sun Pharmaceutical Industries Inc.1$21
Tolmar Pharmaceuticals, Inc.1$21
Kyowa Kirin, Inc.1$20
Coherus Oncology, Inc.1$20
Dova Pharmaceuticals1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,510 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$31,661
Medicare patients
291
Services billed
530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →